Analysis of expression of the melanoma-associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in in situ lesions

Journal of Immunotherapy

Volumn 19, Issue 3, 1996, Pages 192-205

  Marincola, Francesco M ^a   Hijazi, Yasmine M ^b   Fetsch, Patricia ^b   Salgaller, Michael L ^a   Rivoltini, Licia ^a   Cormier, Janice ^a   Simonis, Toni B ^a   Duray, Paul H ^b   Herlyn, Meenhard ^c   Kawakami, Yutaka ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

FNA; GP100; MART 1; Melanoma

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN; HLA A2 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMB 45; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; ASPIRATION BIOPSY; CANCER CELL CULTURE; CLINICAL ARTICLE; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE CLONE; MELANOMA CELL; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 8944254243     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199605000-00004     Document Type: Article

References (49)

1. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl AcadSci USA 1994;91:3515-9.
3. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl AcadSci USA 1994;91:6458-62.
5. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
6. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
7. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
8. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-in-filtrating lymphocytes [published erratum appears in J Exp Med 1995;181:1261]. J Exp Med 1995;181:799-804.
9. Kang X, Kawakami Y, El-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-8.
10. Robbins PF, El-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
11. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
12. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report [see comments]. N Engl J Med 1988; 319: 1676-80.
13. Yamaguchi Y, Suda T, Shiozaki H, et al. Role of IL-5 in IL-2-induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2. J Immunol 1990;145:873-7.
14. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170: 797-810.
15. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele. J Immunol 1991;146:1692-9.
16. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
17. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
18. Salgaller ML, Afshar A, Marineóla FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
19. Rosenberg SA, Yannelli JR., Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
20. Ferrone S, Marineóla FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:487-94.
21. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures. J Immunol 1990;144:4487-95.
22. Marineóla FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
23. Moss DJ, Misko IS, Burrows SR, Burman K, McCarthy R, Sculley TB. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 1988; 331:719-21.
24. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF. Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science 1977;196:1456-8.
25. Young RK, Cailleau RM, Mackay B, Reeves WJ Jr. Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro 1974; 9:239-45.
26. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-23.
27. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985;45:5670-6.
28. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol 1980;1:121-9.
29. Marincola FM, Shamamian P, Simonis TB, et al. Locus specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 1994;16:13-23.
30. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
31. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988; 168: 2183-91.
32. Hopkins KA, van Leeuwen A, Tardiff GN, LeFor WM. Lymphotoxicity testing. In: Zachary AA, Teresi GA, eds. ASHI laboratory manual. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, 1990:195-9.
33. Adams SD, Marincola FM, Shamamian P, Simonis TB, Davey RJ. HLA class I typing of tumor cell lines using fluorescence activated cell sorting (FACS) and complement mediated cytotoxicity (CDC). Hum Immunol 1994;37 (suppl):149.
34. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994;39:105-16.
35. Schild H, Rotzschke O, Kalbacher H, Rammensee HG. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990;247:1587-9.
36. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class IMHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-3.
37. Ruiz-Cabello F, Perez-Ayala M, Gomez O, et al. Molecular analysis of MHC-class-I alterations in human tumor cell lines. Int J Cancer Suppl 1991;6:123-30.
38. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 1993; 91:684-92.
39. D’Urso CM, Wang ZG, Cao Y, Tatake R, Zef TRA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991;87:284-92.
40. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing mono morphic determinants of class I human leukocyte antigens. Cancer Res 1993;53:3349-54.
41. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
42. Restifo NP, Marineóla FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. The loss of functional b2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J Natl Cancer Inst 1996; 88: 100-8.
43. Brocker EB, Suter L, Bruggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985;36:29-35.
44. Holzmann B, Brocker EB, Lehmann JM, et al. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-71.
45. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48:1019-25.
46. Chen Y-T, Stockert E, Tsang S, Coplan KE, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125-9.
47. Lee TD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In: Lee J, ed. The HLA system. New York: Springer-Verlag, 1990: 141-78.
48. Marineóla FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appears in Cancer Res 1993; 53:3846]. Cancer Res 1992; 52: 6561-6.
49. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immuno histochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989; 49:7086-92.